Moderately to Severely Active Ulcerative Colitis, Moderately to Severely Active Crohn's Disease, Juvenile Psoriatic Arthritis
Conditions
Brief summary
AEs, SAEs, AEs leading to discontinuation of study intervention, and AEs of special interest (as determined for each indication)., Clinical laboratory hematology and chemistry., Injection-site reactions, AEs of worsening of the disease under study., An addition of concomitant therapy due to loss of response.
Interventions
Sponsors
Janssen - Cilag International
Eligibility
Sex/Gender
All
Age
0 Years to 17 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| AEs, SAEs, AEs leading to discontinuation of study intervention, and AEs of special interest (as determined for each indication)., Clinical laboratory hematology and chemistry., Injection-site reactions, AEs of worsening of the disease under study., An addition of concomitant therapy due to loss of response. | — |
Countries
Belgium, France, Germany, Hungary, Italy, Poland, Spain
Outcome results
None listed